Opioids Market to Reach US$ 61.1 Billion by 2033 Amid Rising Demand for Pain Management Solutions - Persistence Market Research

The global opioids market is one of the largest segments in the pharmaceutical industry, predominantly driven by the widespread demand for effective pain management solutions. The opioid class of drugs is considered the gold standard in treating moderate to severe pain, especially for patients dealing with chronic conditions such as cancer, chronic obstructive pulmonary disease (COPD), and severe traumatic injuries. According to Persistence Market Research, the opioids market was valued at US$ 42.9 billion in 2022, and it is expected to expand at a CAGR of 3.3% to reach US$ 61.1 billion by 2033. This growth trajectory is influenced by several key factors, including the rising prevalence of chronic diseases, an aging population, and increasing awareness regarding opioids as effective pain relief agents.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/3066

Overview of the Opioids Market

Opioids are a class of drugs derived from the poppy plant, and they are primarily used for pain management. The opioids market is diverse, with various formulations such as morphine, fentanyl, codeine, and oxycodone, each addressing different levels and types of pain. The market growth is underpinned by several critical factors, including the global increase in cancer diagnoses, rising healthcare needs of the elderly population, and ongoing advancements in opioid formulations aimed at improving efficacy and reducing side effects.

Key market drivers include the growing number of patients with chronic diseases, particularly those suffering from cancer, COPD, and severe trauma-related pain. The opioid class of drugs is particularly favored due to its potency and effectiveness in managing pain in both acute and chronic settings. Additionally, the aging population globally is likely to escalate the demand for opioids, as older individuals are more susceptible to conditions that require long-term pain management.

In terms of market segmentation, morphine is expected to continue holding the largest share of the opioids market, with a projected value of US$ 15.9 billion by 2023. By region, North America stands out as the leading geographical segment, with the U.S. accounting for the majority of the market share, driven by high healthcare expenditures, a large population suffering from chronic pain, and established medical frameworks that favor opioid prescriptions.

Key Highlights from the Report:

✦ Global opioids market value was US$ 42.9 Bn in 2022.
✦ The market is projected to grow at a CAGR of 3.3% from 2023 to 2033.
✦ Morphine holds the largest market share, projected at US$ 15.9 Bn by 2023.
✦ The opioids market accounts for 55.6% of the global analgesics market share.
✦ The U.S. dominates the market, with 93.1% of North America's opioids market share.
✦ Increased demand for opioids due to rising chronic disease prevalence and aging population.

Market Segmentation

The opioids market is segmented by various factors, including product type, end-user, and application. Among the product types, morphine, fentanyl, codeine, and oxycodone are some of the leading categories, with morphine leading the market share due to its widespread usage in both hospital and palliative care settings. These drugs are used primarily for pain management in various settings such as hospitals, cancer care centers, and long-term care facilities.

Hospitals are the dominant end-user segment in the opioids market. Hospital pharmacies account for the largest share of opioid sales due to the frequent prescription of opioids for post-operative care and terminally ill patients. On the other hand, retail pharmacies and online platforms are growing distribution channels due to the increase in at-home pain management and telemedicine services.

The application of opioids spans multiple domains, from chronic pain relief in conditions like cancer and back pain to acute pain management post-surgery. Pain relief for neuropathic pain is emerging as a key application area, with opioid prescriptions expanding as healthcare professionals better understand the need for targeted pain management.

Regional Insights

Regionally, North America is the largest market for opioids, particularly in the U.S., where opioid prescriptions for pain management are prevalent in both chronic and post-operative care. The market in North America is largely influenced by the rising prevalence of chronic diseases, awareness regarding palliative care, and widespread insurance coverage that facilitates opioid access for patients.

Europe follows closely behind, with Germany being a major contributor due to the increasing demand for opioids for cancer and terminal illnesses. Additionally, East Asia, especially China, is also witnessing growing demand for opioids. The rising elderly population and the increasing number of terminal illnesses, especially among older adults, are key factors contributing to the market's expansion in this region.

Market Drivers

The primary driver of the opioids market is the increasing prevalence of chronic diseases such as cancer, COPD, and various neurological disorders, which often require opioid medications for pain relief. Chronic pain affects millions of people worldwide, and opioids are often the most effective means of providing relief for individuals suffering from such conditions.

The aging population is another significant driver, as older individuals are more likely to experience chronic pain due to conditions like osteoarthritis, cancer, and cardiovascular diseases. In addition, there is an increasing awareness about opioids and their role in pain management, particularly in countries like the U.S., where palliative care and Opioid Maintenance Treatment (OMT) programs have gained traction.

Market Restraints

Despite the growing demand for opioids, there are several challenges hindering market growth. The severity of opioid misuse and addiction has led to increased regulations around prescribing practices. Opioid abuse has become a global concern, especially in North America, where overdose deaths have spiked in recent years. This has led to stricter regulations and, in some cases, reluctance from healthcare providers to prescribe opioids.

Another restraint is the adverse side effects associated with long-term opioid use. Respiratory depression, addiction, and the potential for overdose are significant risks that can limit the widespread prescription of opioids. Additionally, alternative pain management solutions such as NSAIDs and non-pharmacological interventions are growing in popularity, further impacting the demand for opioids.

Market Opportunities

The opioids market presents numerous opportunities, particularly in emerging markets where access to pain management is still limited. Companies expanding into regions like Africa and South America, where the demand for opioids is expected to rise due to increasing healthcare access and rising disease prevalence, stand to benefit significantly.

Furthermore, there are growing opportunities in the development of novel opioid formulations that aim to reduce side effects and minimize abuse potential. For example, the development of abuse-deterrent formulations of opioids could potentially reduce misuse while ensuring that patients in need of pain management have access to necessary medications.

Reasons to Buy the Report

✔ Get insights into the global opioid market's growth trajectory from 2023 to 2033.
✔ Understand key drivers such as chronic diseases and aging population that are shaping market growth.
✔ Analyze regional market trends and regional leaders, with a focus on North America and Europe.
✔ Identify emerging market opportunities, including developing regions and novel opioid formulations.
✔ Learn about market restraints and regulatory challenges affecting the opioid industry globally.

Company Insights

• Pfizer Inc.
• Johnson & Johnson
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Endo Pharmaceuticals Inc.

Recent Developments:

In August 2020, Trevena Inc. received U.S. FDA approval for Olinvyk (oliceridine), an opioid agonist for pain management.

Johnson & Johnson is focusing on abuse-deterrent formulations to address opioid misuse concerns.

Conclusion

The opioids market is poised for steady growth, driven by the rising global prevalence of chronic pain and increasing demand for effective pain relief solutions. Despite the challenges posed by opioid misuse and addiction, advancements in formulation technology and expanded access in emerging markets provide significant opportunities for growth. As the healthcare industry continues to evolve, so too will the demand for opioids, ensuring the market remains a key segment in global pharmaceuticals.

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.